Management of renal dysfunction in multiple myeloma

Area of Science:

• Nephrology
• Hematology
• Oncology

Background:

• Multiple myeloma frequently causes renal dysfunction, indicating higher tumor burden and aggressive disease.
• Renal impairment in multiple myeloma patients increases morbidity and complicates treatment tolerance.

Purpose of the Study:

• To outline an effective treatment strategy for multiple myeloma patients with renal insufficiency.
• To emphasize the importance of aggressive treatment and consider newer therapeutic options like thalidomide.

Main Methods:

• Recommended treatment sequence for newly diagnosed multiple myeloma with renal insufficiency (creatinine > 2 mg/dL): hypercalcemia correction, VAD induction therapy, stem cell collection, and high-dose melphalan with autologous stem cell transplant.
• Consideration of dialysis support if renal function does not improve with initial therapy.
• Tailoring treatment for patients developing renal insufficiency later in the disease course based on history, disease status, and performance status.

Main Results:

• Reversal of renal insufficiency leads to survival outcomes comparable to patients with normal renal function.
• Aggressive treatment regimens are necessary for patients with multiple myeloma and renal impairment.

Conclusions:

• Early and aggressive treatment of multiple myeloma with renal insufficiency is vital for improving survival outcomes.
• Treatment strategies must account for renal function, incorporating options like thalidomide and stem cell transplantation.
• Dialysis and tailored approaches are essential for managing renal complications in multiple myeloma.